February 20, 2014

Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection

Liver Int. 2014 Feb 16. doi: 10.1111/liv.12502. [Epub ahead of print]

Zavaglia C1, Silini E, Mangia A, Airoldi A, Piazzolla V, Vangeli M, Stigliano R, Foschi A, Mazzarelli C, Tinelli C.


AIMS: Aim of the study was to assess if host (immunogenetic traits, age, sex), exogenous (alcohol) or viral factors (viral type, past HBV infection) might affect the progression of chronic hepatitis C to liver decompensation or the development of HCC in a cohort of patients exposed to a single blood transfusion prior to the introduction of anti-HCV screening.

METHODS: Two hundred and forty-eight patients with a history of a single exposure to blood or blood products prior to 1990 were retrospectively considered. Patients were devoid of other risk factors of liver disease or immunosuppression and naïve to antiviral therapies. Eight baseline variables were assessed: age at transfusion, sex, HBV core antibody, immunogenetic profile (DRB1*11, DRB1*1104, DRB1*07), HCV genotype and alcohol consumption.

RESULTS: The follow-up was 22 (SD 11) years. Sixty-eight patients (27%) progressed to hepatic decompensation over a median period of 22.5 years (IQR: 14-30) and 41 patients (16%) developed HCC over a median period of 31 years (IQR: 24 - 38). The cumulative incidence of liver failure was 0.4% (95%CI: 0.1 - 3.1), 4.9% (95%CI: 2.6 - 9.3) and 16.2% (95%CI: 10.4 - 24.7) at 10, 20 and 30 years after blood transfusion, respectively. By univariate analysis, only age at transfusion was correlated with the risk of decompensation. Stratifying the age of transfusion by tertiles, the incidence of hepatic decompensation was 0.7% per year in patients transfused at ≤24 years of age as compared with 1.2% and 1.9% per year in those transfused at 25-35 and >36 years of age, respectively (HR 5.5, 95%CI: 2.78-10.7, p<0.001). The risk of HCC development was correlated by univariate analysis with age at transfusion (as continuous variable, HR 1.12, 95% CI 1.08-1.16 per year of age, p<0.001, >36 compared to ≤24 years, HR 10.3, 95% CI 3.9-26.9, p<0.001) and male sex (HR 4.2, 95% CI 1.7-10, p=0.001). Multivariate analysis confirmed age at transfusion and male sex as independent predictors of HCC development (HR 1.12 per year [95% CI: 1.08-1.16], p<0.001 and HR 5.4 [95% CI 2.2-13.2], p<0.001, respectively)

CONCLUSIONS: In patients with transfusion-acquired HCV infection, age at transfusion affect the risk for hepatic decompensation. Age at transfusion and male sex are also independent risk factors for HCC development. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

KEYWORDS: HCV , blood transfusion, chronic hepatitis C, hepatic decompensation, hepatocellular carcinoma

PMID: 24529078 [PubMed - as supplied by publisher]


Drug Can Possibly Treat Acetaminophen Poisoning

Thu, 02/20/2014 - 2:07pm


The human liver can safely process up to 4 grams (8 pills) of acetaminophen, best known as Tylenol, over 24 hours. Surpassing that amount risks poisoning or killing liver cells. (Source: Harvard University/B. D. Colen)

Harvard stem cell scientists studying the effect of nitric oxide on liver growth and regeneration appear to have serendipitously discovered a markedly improved treatment for liver damage caused by acetaminophen toxicity, the root of half of the hospital visits involving acute liver failure in the United States.

The human liver can safely process up to 4 grams (8 pills) of acetaminophen, best known as Tylenol, over 24 hours. Surpassing that amount risks poisoning or killing liver cells. Accidental acetaminophen overdoses commonly occur when people who feel sick but don’t know the dangers posed by the over-the-counter pain and fever reducer exceed the safe dosage. Such poisoning kills hundreds of people each year.

Writing in the journal Cell Reports, the researchers described how nitric oxide, which is commonly used to relax cardiac blood vessels in patients with heart disease, enhances liver growth and regeneration, independent of its effect on blood vessels. Using zebrafish and mice, the research team also showed how manipulating these pathways with drugs could improve treatment of toxic liver injury caused by acetaminophen overdose.

The only federally approved treatment for acetaminophen toxicity, N-acetylcysteine (NAC), is most effective if a patient seeks medical help within 8 to 12 hours of overdose. Unfortunately, most overdose-specific symptoms, such as confusion and intestinal bleeding, don’t occur until the liver injury is critical.

“We tried to model that in our studies where we gave fish Tylenol first, waited 18 hours, and gave them a new nitric oxide-based drug combined with the clinically approved drug,” said study co-senior author Wolfram Goessling of the Harvard Stem Cell Institute. “These drugs worked together to improve liver injury even when out of the previously established therapeutic window, and so we think there’s significant potential for clinical application.”

Goessling and his research associates happened upon the nitric oxide-liver injury connection while investigating the signaling pathways that are important for liver development. Goessling’s lab, which he shares with study co-senior author Trista North, screened thousands of known drugs on zebrafish embryos to see which produced a bigger or smaller liver. The compounds with the most dramatic effect were a family of drugs that affect nitric oxide and nitric oxide signaling.

Andrew Cox, a postdoctoral fellow in Goessling’s lab, conducted a series of experiments to show that nitric oxide enhanced liver formation during organ development in zebrafish and that blocking nitric oxide led to smaller, less-developed livers. Further investigation found that nitric oxide worked through different pathways in the liver than it did in the blood vessels, where its ability to regulate blood flow has been well established.

“During these experiments, we found a recently recognized pathway, called protein nitrosylation, where the activity of proteins gets changed by nitric oxide,” Goessling said. “We think that’s the basic principle behind how it works in liver development.”

The members of Goessling and North’s lab found it was possible to enhance liver growth and regeneration by disrupting the nitrosylation pathway so that nitric oxide could better change proteins in the liver. They found a nitrosylation enhancer currently used in clinical trials for other purposes and began testing it in clinical models of illnesses such as Tylenol overdose, where it proved successful.

“This potential drug doesn’t only work in fish,” Goessling said. “We did use mouse models to show that this might have relevance to human disease.”

If the nitrosylation drug for liver toxicity reaches clinical trials, it would join a handful of other drugs developed from zebrafish research that originated from Harvard Stem Cell Institute labs.

Last year, a compound discovered by North and Goessling while they were working as postdoctoral fellows in the lab of Leonard Zon was found to expand cord blood during hematopoietic stem cell transplants in a Phase 1b clinical trial. Another drug for melanoma, also discovered in the Zon lab, reached the federal Food and Drug Administration approval process in 2011.

Date: February 20, 2014

Source: Harvard University


Active at night, sleepy all day - Sleep disturbances in patients with hepatitis C virus infection

Provided by NATAP

Download the PDF here

Article in Press

Journal of Hepatology 2014
Meike Heeren, Faina Sojref, Ramona Schuppner, Hans Worthmann, Henning Pflugrad, Anita B. Tryc, Thomas Pasedag, Karin Weissenborn
Department of Neurology, Hannover Medical School, Hannover, Germany

"The purpose of this study was to characterize the feature and degree of sleep disturbances in HCV-infected patients without relevant liver disease and to clarify the patients' symptoms. Furthermore we were interested to analyze the relationship between sleep disturbances, neuropsychiatric symptoms and health-related quality of life.......In conclusion, our data showed altered sleep quality in a group of patients with HCV infection associated neuropsychiatric symptoms but only mild liver disease.....wrist actigraphy showed sleep disturbances reflected by a higher nocturnal activity and poorer sleep efficiency........Our data indicate that chronic fatigue is associated with bad sleep quality and increased nocturnal activity in HCV-infected patients.....The patients achieved higher scores for depression, fatigue and sleep disturbances and lower quality of life scores than the healthy controls. Actigraphy showed higher nocturnal activity and worse sleepefficiency in the patients, while the 24-h activity level did not differ between groups. Fatigue and quality of life scores correlated with bad sleep quality and daytime sleepiness."

HIV & Sleep


"On the basis of experimental studies it is known that sleep disturbances are associated with alterations of the immune system.......The alteration of cytokine levels both in the periphery as well as in the brain itself could well be involved in the development of sleep disturbances in HCV-infected patients.......In conclusion, our data showed altered sleep quality in a group of patients with HCV infection associated neuropsychiatric symptoms but only mild liver disease.......In summary sleep-wake disturbances are common in cirrhotic patients. The patients suffer from daytime sleepiness and bad sleep quality and some studies showed a phase delay in the sleep patterns of cirrhotic patients. Our patient group with only mild liver disease showed a different feature of sleep disturbances."



Background & Aims
More than 50% of patients with chronic hepatitis C with only mild liver disease complain about chronic fatigue, daytime sleepiness and poor sleep quality. The aim of the present study was to characterize and objectify the sleep disturbances in hepatitis C virus-infected patients.

Twenty-five women who had been infected with hepatitis C virus contaminated anti-D immunoglobulin in 1978/79 and 22 age-matched female healthy controls underwent actigraphy over a period of 5days to measure motor activity and thereby sleep-wake-rhythm and in addition completed questionnaires for depression, health-related quality of life, fatigue and sleep, and a sleep diary. Liver cirrhosis, a history of neurological or psychiatric disease, history of intravenous drug abuse, shift work, or current medication with effect upon the central nervous system were exclusion criteria.

The patients achieved higher scores for depression, fatigue and sleep disturbances and lower quality of life scores than the healthy controls. Actigraphy showed higher nocturnal activity and worse sleep efficiency in the patients, while the 24-h activity level did not differ between groups. Fatigue and quality of life scores correlated with bad sleep quality and daytime sleepiness.

Our data indicate that chronic fatigue is associated with bad sleep quality and increased nocturnal activity in HCV-infected patients suggesting an alteration of sleep architecture behind fatigue in HCV-associated encephalopathy.


About 170 million people worldwide suffer from chronic infection with the hepatitis C virus (HCV), the global prevalence is about 2.35%. In 80% acute hepatitis C infection leads to chronic hepatitis whereas between 1 and 20% - dependent on the presence or absence of risk factors such as older age, male sex, alcohol abuse, or diabetes for example - develop liver cirrhosis [1], [2]. An extremely low rate of liver cirrhosis has been observed in the so-called German Anti-D cohort, a group of women who have been infected with HCV contaminated anti-D immunoglobulin in 1978/79 in Eastern Germany. Wiese et al. reported that only 2% of 1980 women who underwent a follow-up examination 25years after the infection showed liver cirrhosis or a pre-cirrhotic stage while 62% "complained of constitutional symptoms such as reduced exertional capacity, weakness and fatigue, abdominal distention, arthralgia, myalgia, or headaches" [2].

Hepatologists are well aware of the extrahepatic manifestations of the HCV-infection and it has been acknowledged recently that the central nervous system is most frequently affected [3].

Symptoms like chronic fatigue, mood disturbances and cognitive dysfunction occur in HCV infected patients with none or only mild liver disease and are accompanied with a reduction of health-related quality of life. The most frequent symptom with more than half of the patients affected is fatigue. Of note, this holds true also in the absence of advanced liver disease or ongoing antiviral therapy with interferon alpha [4]. In detail, chronic HCV infected patients complain about daytime fatigue and poor sleep quality. Up to now these symptoms are not well described in the literature and the pathogenesis is still unclear [5].

The purpose of this study was to characterize the feature and degree of sleep disturbances in HCV-infected patients without relevant liver disease and to clarify the patients' symptoms. Furthermore we were interested to analyze the relationship between sleep disturbances, neuropsychiatric symptoms and health-related quality of life.

Patients and methods

Patients and controls

One-hundred-forty-three members of HCV patient support groups for women who had been infected with HCV-contaminated anti-D immunoglobulin in 1978/79 were contacted in writing and asked if they were interested in taking part in the study. These patients were considered especially suitable to study the effect of HCV-infection upon sleep features and quality because neither co-infection, nor substance abuse or other concomitant disorders could probably bias the results. Eleven patients had moved and their current address was not available, two patients refused to take part in the study. Forty-two women answered our letter and showed interest (Fig. 1).

These 42 women were contacted via phone for a structured interview concerning the exclusion criteria such as liver cirrhosis, a history of neurological or psychiatric disease, history of intravenous drug abuse, shift work, or current medication with effect upon the central nervous system. Thereafter 17 patients had to be excluded from the study because of current therapy with antidepressants (n=10), opioids or benzodiazepine (n=5) or current interferon therapy (n=2) (Fig. 1).

Finally, twenty-five women were included into the study. The time span since infection was more than 30years and the genotype of the virus 1b in all patients. Liver cirrhosis or severe fibrosis was excluded by calculation of the APRI (aspartate aminotransferase-to-platelet ratio index) score [6], by ultrasound of the liver and/or by liver biopsy.

22 age-adjusted female control subjects were recruited from the clinic staff as well as family and friends of working group members applying the same exclusion criteria as for the patients. Patients and controls gave their written informed consent.

The study has been performed according to the 1975 Declaration of Helsinki and has been approved by the local ethics committee.


The patients and controls completed several questionnaires including the Pittsburgh sleep quality index (PSQI) [7], the Epworth sleepiness scale (ESS) [8], the fatigue impact scale (FIS) [9], the Beck depression inventory (BDI) [10], the hospital anxiety and depression scale (HADS) [11] and the SF-36 [12]. The PSQI is a subjective measure of sleep quality over the previous 4weeks. The questionnaire consists of 17 items based on components of quality, latency, duration, efficiency, disturbance, use of sleeping medication and daytime dysfunction. The global score varies between 0 and 21. A score 5 can be considered suggestive of significant sleep disturbance. The ESS intends to measure daytime sleepiness. Each item is rated on a 4-point scale. The global score ranges between 0 and 24, with 10 as a cut-off score for pathological daytime sleepiness. The FIS is a self-report scale to measure the impact of fatigue upon patients' daily living activities. It contains 40 items with a scale from 0 to 4. The total score varies between 0 (no fatigue) and 160 (severe fatigue), we choose 50 as a suggested cut-off for pathological fatigue considering own data from healthy controls from former studies. The BDI is a self report scale to measure depression. The questionnaire contains 21 items and a 4-point response scale, ranging from 0 (minimal) to 3 (severe). The global score ranges from 0 to 63, a score 18 can be considered as pathologic. The Hospital Anxiety and Depression Scale (HADS) has been developed for use in in-hospital patients with internal disease to assess emotional alterations. It is a 14 items scale, each scored from 0 to 3. The global range varies between 0 and 21 for anxiety and depression, respectively, with a score 11 indicating anxiety or depression. The Short-Form questionnaire (SF-36) is a survey with 36 questions to measure health-related quality of life (QoL). It provides scores for 8 health domains which can be summarized to a physical and a mental score with a maximum of 400 points for each of the two domains. The cut-off depends on age and sex. The patients' results were evaluated accordingly.

Sleep diary

The patients were requested to fill in a sleep diary to record the "in bed time", time to sleep onset, number of awakenings, "out of bed time", daytime nap, coffee and alcohol consume for the days studied.


Actigraphy was used to measure motor activity of the subjects throughout a period of 5days. The actigraph is a small device (38mmX37mmX18mm, weight 26g) which is worn on the wrist of the non-dominant hand. We used the accelerometer ActiGraph Monitor GT1M and GT3X (ActiGraph, Pensacola, USA). Both contain a sensor which detects motion with linear piezoelectric accelerometer in a vertical axis [13]. The signal is summarized over epochs of 60s, and given as counts per minute (cpm). Patients and controls were advised to wear the device from Sunday to Saturday 24h per day and to only take it off for washing the dishes or taking a shower. The data stored were downloaded to a computer using the ActiLife 5.0 software. Because of the varying sleep-wake-rhythm during the weekend only data covering the time span from Monday 12pm until Friday 12pm were considered for further analysis.

\e used the floating window algorithm and 20min of consecutive zero counts to identify the non-wear time. Afterwards the data were visually inspected to ensure that information recorded in the sleep diary corresponded with the accelerometer output. The periods of non-wear time as indicated by the participants were excluded from further analysis.

For the sleep scoring we completed the stored data by adding the "in bed time" and "out of bed time" from the sleep diary. The software provides the following parameters:

Sleep onset (the first minute that the algorithm scores "asleep"), total sleep time (the total number of minutes scored as "asleep"), sleep efficiency (number of sleep minutes divided by the total number of minutes the patient was in bed), wake after sleep onset (WASO; the total number of minutes the subject was awake after sleep onset occurred), average awakening (the average length in minutes of all awakening episodes), total counts (total actigraphy counts summed up for the entire sleep period).

The total numbers of epochs stored during the measurement (4X24h) were averaged to measure different categories of activity intensity in a 24h period. We selected 100 counts per minute (cpm) as a cut-point for sedentary behaviour, 100-759cpm for light physical activity, 760-1951cpm for lifestyle physical activity, 1952-5724cpm for moderate physical activity and >5725cpm for vigorous physical activity [14], [15]. In addition we combined the moderate physical activity and vigorous physical activity counts into one class (MVPA >1952cpm) for further analysis as described by Matthews et al. [14]. In addition to the "counts" the data provided bouts of activity. A minimum bout length was 10min, the minimum count level to be considered as bout was 1953cpm and the drop time was 2min [15], [16].

Statistical analysis

Statistical analysis was done using SPSS Version 20. If the data were normally distributed, the results of the questionnaires and actigraphy parameters are summarised as mean values and standard deviations. For not normally distributed data the results are given as median and 25th-75th percentile. A comparison between patients' and control data was performed using the unpaired Student's t test or the Mann-Whitney-U-test accordingly. Spearman correlation was used to look for a relationship between fatigue, QoL and sleep parameters and the actigraphy results because they were not normally distributed. The level of significance was set at a p value of <0.05. In case of multiple comparisons the Bonferroni-Holm correction was applied.


The data of 5 patients and 3 controls had to be excluded from further analysis due to device dysfunction (n=3), insufficient number of monitoring days (n=4) or missing sleep diary (n=1). Thus finally data of 20 patients (age 56.8±4.2) and 19 controls (age 55.3±4.2) were considered for analysis. Six patients had been treated with interferon more than 7years ago. Eight patients were HCV PCR negative, seven spontaneously and one after therapy.

Liver cirrhosis was excluded based on clinical, ultrasound and laboratory data. Liver biopsy has in addition been performed in 3 patients and showed ISHAK 1 fibrosis in 2 and ISHAK 2 fibrosis in one patient. In the other 17 patients liver biopsy was not indicated considering the clinical course as well as ultrasound and laboratory findings. In these patients the APRI score was in median 0.14 (25th-75th percentile: 0.120-0.265).

Five patients are current smokers and 9 patients reported light to moderate alcohol consumption. In the control group 4 women are current smokers and 14 reported light-to-moderate alcohol consumption.


The results of the questionnaires differed significantly between the HCV-infected patients and the controls, while there was no difference between PCR positive and PCR negative patients (Table 1), or patients with or without alcohol or nicotine consumption. The patients scored higher in the FIS than the controls (p<0.001) showing pathological FIS scores (>50) in 14 (70%). They also showed significantly worse sleep quality. Nineteen of the 20 patients (95%) had a PSQI score indicating sleep disturbances. The patients had also significantly higher ESS scores; 50% showed scores representing pathological daytime sleepiness. Also the depression, anxiety and QoL scores differed significantly between patients and controls (all p<0.05). Thirteen patients (65%) revealed a pathological result in the anxiety subscore and 8 (40%) in the depression subscore of the HADS. Fifty percent of the patients showed pathological results in the BDI (Table 1). The patients had significantly worse quality of life scores compared to the controls (for SF-36 sum-score, physical and mental sub-score p<0.001).

Wrist actigraphy

\he patients showed a significantly higher nocturnal activity than the controls while the time they spent in bed was significantly longer. The time the patients were awake after sleep onset (WASO) and average awakening length at night were also significantly longer. Accordingly they had a worse sleep efficiency than the healthy women (Table 2, Fig. 2).

A subgroup analysis between the PCR positive and negative patients did not show significant group differences except of for the minutes of wake after sleep onset (p=0.036), where the PCR negative patients exceeded the PCR positive ones (Table 2).

For analysis on a daily basis we separated for the activity level. In a 24h period the patients and controls engaged most of the time in sedentary. We could only show that the controls stay a longer time in light physical activity in comparison to the patients. The other activity parameters did not differ significantly between both groups (Table 3). In contrast to the activity level for the night (total counts in entire sleep period, Table 2) the activity level over a whole day (total counts in bouts/24h) was almost the same in the two groups thereby indicating a higher daytime activity in the controls compared to the patients (Table 3).

Using Spearman rank correlation analysis we found a significant relationship in the patient group between the FIS, the PSQI and the ESS respectively (p<0.001). Patients with a higher fatigue score had worse sleep quality and more severe daytime sleepiness. There was no significant correlation between the results of the FIS, the PSQI, the ESS and the actigraphy parameters (Table 4, Table 5). Accordingly the SF 36 results (sum-score, physical and mental score) correlated negatively with the sleep questionnaires (p<0.05) but not with the actigraphy data (Table 4).


In the last two decades there has been growing evidence that infection with the hepatitis C virus can lead to brain dysfunction in the absence of severe liver disease [3], [17], [18], [19], [20]. The patients complain about chronic fatigue, cognitive dysfunction, a reduced quality of life and depression. Furthermore they report sleep disturbances such as daytime sleepiness and poor sleep quality [21]. The pathology behind is unclear, as is the interrelationship between these different symptoms.

In the present study we examined 20 women, who had been infected with HCV more than 30years ago but had not developed relevant liver disease, and 19 age-adjusted female healthy controls using a battery of sleep questionnaires and wrist actigraphy.

Like HCV-infected patients in former studies [4], [19], [20] the patients revealed increased scores for depression and anxiety, and decreased QoL scores. Sleep questionnaires indicated a significant alteration of sleep quality, and in accordance with the characteristic complaints wrist actigraphy showed sleep disturbances reflected by a higher nocturnal activity and poorer sleep efficiency.

It must be emphasized that our patients had no significant liver disease, since sleep disturbances are known as a frequent complication of liver cirrhosis. C—rdoba et al. [22] studied 20 patients with liver cirrhosis and 20 healthy controls with a sleep questionnaire and actigraphy for 5 consecutive days. The cirrhotic patients showed a fragmented sleep at night, a higher nocturnal activity and a reduced physical activity over a 24h period compared to the controls. Patients with unsatisfactory sleep showed a shift of activity toward later hours of the day. In 2008 Mostacci et al. [23] studied 178 patients with a diagnosis of non-alcohol-related liver cirrhosis and 178 healthy controls. Patients with cirrhosis showed a significantly higher prevalence of daytime sleepiness and bad sleep quality with difficulties in falling asleep and frequent nocturnal awakenings. Those patients with minimal hepatic encephalopathy had more pronounced daytime sleepiness and night time sleep disturbances in contrast to the other cirrhotic patients. A comparison between the patient groups with pathological and normal blood ammonia level did not show any differences in the parameters of sleep quality and sleep habits. Montagnese and co-workers [24] assessed sleep-wake-disturbances in 87 patients with liver cirrhosis with and without minimal/overt hepatic encephalopathy and 19 healthy controls. They found higher PSQI und ESS scores in the patients compared to the control group. In contrast to the study of Mostacci and co-workers there was no significant correlation between the sleep questionnaires and the presence of hepatic encephalopathy. In concordance to the findings of C—rdoba and co-workers evening type cirrhotic patients took longer to fall asleep and the sleep quality was worse than in patients with earlier sleep timing.

In summary sleep-wake disturbances are common in cirrhotic patients. The patients suffer from daytime sleepiness and bad sleep quality and some studies showed a phase delay in the sleep patterns of cirrhotic patients.

Our patient group with only mild liver disease showed a different feature of sleep disturbances. Although they showed a higher nocturnal activity as well, they had a similar 24h activity level compared to controls and no shift in the sleep-wake-rhythm. Thus the pathogenesis behind is probably different from that in cirrhotic patients with sleep disorder.

Our patient group consists of women who had been infected with hepatitis C virus contaminated anti-D immunoglobulin in the 1970s. Patients with risk factors for developing fatigue (independent of the HCV infection) like intravenous drug abuse and co-infection with the human immunodeficiency virus (HIV) were excluded. Fatigue and depression are known as side effects of interferon therapy in HCV patients [25]. Of note, interferon therapy had been finished at least 7years ago in the 6 patients of our group who had ever been treated. None of the subjects in this study took any medication that could be hold responsible for fatigue and sleep disturbances. However, nearly half of the patients (and 73% of the controls) reported slight to moderate alcohol consumption and 25% had a smoking habit. According to Yamini et al. [26] both factors are associated with the presence of depression, fatigue and sleep disturbances in patients with HCV-infection. They evaluated clinical data of 800 HCV-infected patients for the impact of past and current tobacco use or drinking habits, comorbidities such as diabetes mellitus or hyperlipidemia, history of interferon treatment, fibrosis stage and others upon the presence of depression, fatigue and difficulty sleeping in these patients. The analysis showed a significant relationship between past and present tobacco use and past alcohol use and the presence of depression, between past and present tobacco use and current alcohol use and fatigue, as well as between past and present tobacco use and difficulty sleeping in these patients. In contrast social drinking was associated with a lower risk of difficulty sleeping. Of note, their patient cohort differed significantly from that examined in our study: about half of their patients had a history of drug abuse, one third were heavy drinkers, more than 50% were male and about 50% had advanced fibrosis (28%) or cirrhosis (18%). Depression was present in about 30%, fatigue in 45% and difficulty sleeping in only 3.8%. Considering these differences and the fact that both, smoking and drinking habits of the patients in our cohort were only slight to moderate these factors are unlikely having influenced the results.

Eight of our 20 patients were HCV PCR negative, 7 of them had cleared the virus spontaneously. These HCV PCR negative patients were included into the study and treated as homologous to the HCV PCR positive patients because we have repeatedly shown in previous studies that both, HCV PCR positive and negative patients may develop HCV-infection-associated encephalopathy and present with identical symptoms and findings in brain imaging such as magnetic resonance spectroscopy, Fluor-Desoxy-Glucose positron emission tomography and single photon emission tomography [19], [20], [27]. Accordingly we did not find a significant difference between both patient groups in the present study as well. In the past several studies have shown that the virus replicates in the brain [28], [29], [30], [31]. Different quasispecies of the virus have been detected post-mortem in the liver and the brain of HCV-infected patients. In 2002 Radkowski et al. detected negative strand HCV-RNA, a viral replication intermediary, in autopsy brain tissue of three out of six HCV-infected patients.

As an indication for viral brain compartmentalization in two of these patients viral sequences amplified from the brain differed from those circulating in serum. Based on a sequence analysis of two different viral regions it was suggested that the brain-derived HCV variants were more closely related to the virus present in the lymphoid system than to virus circulating in serum [28]. Forton et al. also described a close relationship between HCV variants present in brain tissue and in lymph nodes [30]. HCV-RNA was also found in the cerebrospinal fluid (CSF) of eight out of 13 patients. Again the sequences of the brain (CSF) derived virus were closer to those found in peripheral blood mononuclear cells (PBMC) than to those circulating in serum of the patients [30], [31]. HCV-RNA positive and negative strands were detected in CD68-positive cells in the brain, which indicates that the cells harboring HCV are macrophages/microglia. It is suggested that HCV-infected macrophages/monocytes enter the brain via the blood-brain-barrier and induce a neuroinflammatory response that might be causative for the development of neuropsychiatric symptoms [29].

We found a significant correlation between the degree of fatigue as represented by the FIS score and the daytime sleepiness and sleep quality (ESS and PSQI). The findings are in line with the results from Carlson et al. [32] who studied 59 hepatitis C patients with different stages of liver disease. They found a significant relationship between the PSQI and FSS (Fatigue Severity Scale) regardless of the stage of liver disease.

We could not find any significant correlations between the results of the fatigue and sleep questionnaires and the actigraphy parameters. In other words the subjective perception of bad sleep quality must not be accompanied with an equivalent amount of nocturnal motor activity. In sleep research actigraphy is a validated tool for activity based sleep-wake monitoring, which was established by The American Sleep Disorders Association [33], [34], [35], [36]. Of note, some patients having difficulties in falling asleep may have the habit lying in bed for a longer period without movement, others move around in bed very often to try to fall asleep. Thus a possible limitation of the validity of actigraphy is detecting wakefulness during a sleep period [33].

\ limitation of our study is the short actigraphy analysis period of 5 out of 7 recorded days. The International Classification of Sleep Disorders (established by the American Academy of Sleep Medicine) requires a minimum of 7days of actigraphy performed in addition to a sleep diary for being able to demonstrate consistency in the pathology of circadian rhythm disorders. Acebo et al. [37] showed that 5 nights of measuring give reliable estimates for evaluating sleep start time, wake minutes and sleep efficiency. Therefore we choose the recording of the five working days of the week for further analysis taking into account that the weekends are usually characterized by alterations of the sleep habits.

The increased HADS and BDI scores and the significant correlation between HADS and BDI scores and ESS and PSQI scores suggest depression as a possible reason for altered sleep quality in our patients. Former studies in patients with depression had shown a relationship between the extent of depression and actigraphy parameters [38]. This could not be observed in our study. While these findings appear inconsistent on the first view they are comprehensible considering the findings of Golden et al. [39] who were able to show that HADS and BDI scores are falsely positive in patients with HCV infection and do not represent the extent of depression.

On the basis of experimental studies it is known that sleep disturbances are associated with alterations of the immune system. Krueger proposed that sleep is a process which is influenced by cytokines, a part of the peripheral and central immune system [40]. Gershon et al. discussed cytokine effects upon the brain as possible mechanism for the development of fatigue in HCV-infected patients [41]. In 2011 de Almeida studied chronic hepatitis C patients to find an association between the degree of sleep quality (provided by the PSQI and FSS) and peripheral blood immunological and virological biomarkers. They detected a different immunological profile in patients with good sleep quality compared to those with bad sleep quality [42]. Wilkinson et al. detected an upregulation of proinflammatory cytokines IL-1, TNF-alpha, IL-12, and IL-18 in post-mortem brain tissue of hepatitis C patients [43]. The alteration of cytokine levels both in the periphery as well as in the brain itself could well be involved in the development of sleep disturbances in HCV-infected patients.

Finally both pathways might play a role in the development of extrahepatic manifestations of chronic hepatitis C virus infection including sleep disturbances: The virus may induce the peripheral immune system which activates proinflammatory cytokines, while the cytokines may alter brain activity by modifying the neurotransmitter systems. Moreover the hepatitis C virus may induce cerebral cytokine production after crossing the blood brain-barrier and thereby alter neurotransmission.

In conclusion, our data showed altered sleep quality in a group of patients with HCV infection associated neuropsychiatric symptoms but only mild liver disease. The extent and the pathogenesis of sleep disorders in patients who had been infected by HCV has to be clarified in further studies considering the cytokine hypothesis as well as recent findings upon altered neurotransmission in HCV-associated encephalopathy [18], [20], [22], [44].


Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients

Journal of Hepatology
Volume 60, Issue 3 , Pages 530-537, March 2014

Zobair M. Younossi, Mendel E. Singer, Heshaam M. Mir, Linda Henry, Sharon Hunt

Received 12 August 2013; received in revised form 21 October 2013; accepted 7 November 2013. published online 20 November 2013.

See Focus, pages 471–472


Background & Aims
Hepatitis C (HCV) is a common cause of chronic liver disease worldwide. Current standard treatment for genotype-1 patients uses a triple combination of pegylated-interferon alpha (IFN), ribavirin (RBV) and a direct-acting antiviral agent (DAA) with 75–80% sustained virologic response (SVR) rates. The aim is to determine cost-effectiveness of staging-guided vs. treat all HCV genotype-1 patients with interferon-based vs. interferon-free regimens.

A decision analytic Markov model simulating patients until death compared four strategies for treating HCV genotype-1: Triple therapy (IFN, RBV, DAA) with staging-guidance or treat all, and oral IFN-free regimen with staging-guidance or treat all. Strategies with staging initiated treatment at fibrosis stages F2-F4, with staging repeated every 5years until age 70. The reference case was a treatment-naïve 50-year-old. Analysis was repeated for 50% increase in cost of oral therapy. Effectiveness was measured in quality-adjusted life years (QALYs).

Treatment of all patients with oral IFN-free regimen was the most cost-effective strategy, with an ICER of $15,709/QALY at baseline cost of oral therapy. The ICER remained below $50,000/QALY in sensitivity analyses for baseline and +50% cost of oral therapy scenarios. The treat all strategy was also the most effective strategy; associated with the lowest risk of developing advanced liver disease.

Treating all HCV patients with oral IFN-free regimen reduced the number of patients developing advanced liver disease and increased life expectancy. Additionally, IFN-free regimen without staging may be the most cost-effective approach for treating HCV genotype-1 patients. The efficacy and safety of these regimens must be confirmed using randomized clinical trials.

Abbreviations: HCV, hepatitis C, IFN, pegylated, interferon alpha, RBV, ribavirin, DAA, direct, acting antiviral agent, SVR, sustained virologic response, IFN, BV, DAA, Triple therapy, ICER, incremental cost, effectiveness analysis, QALYs, quality, adjusted life years (a standard metric that incorporates both length and quality of life), CHC, chronic hepatitis C, HIV, immunodeficiency virus, TVR, telaprevir, BOC, boceprevir, GT, genotype, F2 or F4, moderate or advanced fibrosis, F0, F1, mild fibrosis, WAC, wholesale acquisition cost, NADAC, National Average Drug Acquisition Cost, CMS, Centers for Medicare and Medicaid Services

Keywords: Interferon-free oral treatment, Cost-effectiveness analysis, Markov model, HCV, DAA


Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

Journal of Hepatology
Volume 60, Issue 3 , Pages 490-499, March 2014

Anna S. Lok, David F. Gardiner, Christophe Hézode, Eric J. Lawitz, Marc Bourlière, Gregory T. Everson, Patrick Marcellin, Maribel Rodriguez-Torres, Stanislas Pol, Lawrence Serfaty, Timothy Eley, Shu-Pang Huang, Jianling Li, Megan Wind-Rotolo, Fei Yu, Fiona McPhee, Dennis M. Grasela, Claudio Pasquinelli

Received 8 August 2013; received in revised form 24 September 2013; accepted 14 October 2013. published online 28 October 2013.

See Focus, pages 471–472


Background & Aims

Patients with chronic hepatitis C virus (HCV) infection and prior null response (<2 log HCV RNA decline after greater than or equal to12weeks of PegIFN/RBV) have limited options. We evaluated daclatasvir plus once- or twice-daily asunaprevir in non-cirrhotic genotype 1 null responders.


In this randomized, phase 2a, open-label, 24-week treatment study, 101 patients received daclatasvir (60mg) once-daily. In addition, 38 genotype 1b patients received asunaprevir (200mg) twice- (DUAL A1) or once-daily (DUAL A2); 36 genotype 1a and 5 genotype 1b patients received asunaprevir twice- (QUAD B1) or once-daily (QUAD B2) plus PegIFN/RBV; and 18 genotype 1a and 4 genotype 1b patients received asunaprevir twice-daily plus ribavirin (TRIPLE B3). The primary endpoint was undetectable HCV RNA 12weeks post-treatment (sustained virologic response, SVR12).


Across all groups, mean HCV RNA was greater than or equal to 6 log IU/ml, and 99% of patients had a non-CC IL28B genotype. SVR12 rates were 78% (A1), 65% (A2), 95% (B1), and 95% (B2). In B3, most genotype 1a patients experienced virologic breakthrough. The most common adverse events were headache, diarrhea, and asthenia. Grade 3–4 aminotransferase elevations were infrequent and not treatment-limiting.


In genotype 1 null responders, daclatasvir plus twice-daily asunaprevir DUAL therapy is effective for most genotype 1b patients, and daclatasvir, asunaprevir, and PegIFN/RBV QUAD therapy is effective for nearly all genotype 1a and 1b patients; but neither DUAL nor TRIPLE therapy is effective for genotype 1a patients. Interferon-free regimens including daclatasvir and twice-daily asunaprevir for genotype 1 null responders should be tailored to subtype.

Abbreviations: HCV, hepatitis C virus, PegIFNα, pegylated interferon alfa-2a, RBV, ribavirin, SVR, sustained virologic response, QUAD,quadruple, DAA, direct-acting antiviral, SVR24, sustained virologic response at 24weeks post-treatment, LLOQ, lower limit of quantification,LOD, limit of detection, SNP, single nucleotide polymorphism, SVR12, sustained virologic response at 12weeks post-treatment, SVR4,sustained virologic response at 4weeks post-treatment, ALT, alanine aminotransferase, AST, aspartate aminotransferase

Keywords: Direct-acting antiviral agents, Sustained virologic response, Hepatitis C treatment, Protease inhibitor, HCV NS5A inhibitor, Non-responders